CL2023001440A1 - Nuevos derivados de indazol acetileno - Google Patents

Nuevos derivados de indazol acetileno

Info

Publication number
CL2023001440A1
CL2023001440A1 CL2023001440A CL2023001440A CL2023001440A1 CL 2023001440 A1 CL2023001440 A1 CL 2023001440A1 CL 2023001440 A CL2023001440 A CL 2023001440A CL 2023001440 A CL2023001440 A CL 2023001440A CL 2023001440 A1 CL2023001440 A1 CL 2023001440A1
Authority
CL
Chile
Prior art keywords
acetylene derivatives
new indazole
indazole
new
acetylene
Prior art date
Application number
CL2023001440A
Other languages
English (en)
Spanish (es)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Goergler Annick
Jaeschke Georg
Obst Sander Ulrike
Ricci Antonio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2023001440A1 publication Critical patent/CL2023001440A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2023001440A 2020-12-01 2023-05-18 Nuevos derivados de indazol acetileno CL2023001440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01

Publications (1)

Publication Number Publication Date
CL2023001440A1 true CL2023001440A1 (es) 2023-12-01

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001440A CL2023001440A1 (es) 2020-12-01 2023-05-18 Nuevos derivados de indazol acetileno

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックegfr阻害剤の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
CN113993591A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂

Also Published As

Publication number Publication date
CN116490182A (zh) 2023-07-25
US20240002390A1 (en) 2024-01-04
JP7840327B2 (ja) 2026-04-03
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CO2023006912A2 (es) 2023-06-09
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CO2026002343A2 (es) Inhibidores de pi3k
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
AR066972A1 (es) Derivados azapeptidicos
CL2023003662A1 (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CL2022001353A1 (es) Inhibidores de egfr
CL2021003139A1 (es) Compuestos tricíclicos
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
CO2022012773A2 (es) Moduladores de nampt
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CL2023003168A1 (es) Moduladores de trex1
CL2023002908A1 (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
AR125963A1 (es) Inhibidores de alk2 quinasa que contienen imidazol
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
MX2022015986A (es) Derivados de aminopirimidinilo.